Phase II Open Label Study of Everolimus (RAD001) in Combination With Letrozole in the Treatment of Post Menopausal Women With Locally Advanced or Metastatic Breast Cancer Women With Estrogen Receptor Positive After Failure of Tamoxifen and or Anestrozole or Examestane.
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Overall Response Rate (ORR)
imaging every 12 weeks
until 1st progression
United States: Food and Drug Administration